Literature DB >> 26344438

[Geriatric intervention in oncology for elderly patients].

O Saint-Jean1, J LeGuen2.   

Abstract

Half of all cancers occur in patients older than 70 years. National cancer plans in France promote the emergence of geriatric oncology, whose aim is that every elder cancer patient receives a pertinent treatment, according to his frailty. Geriatric intervention has been evaluated in various conditions or patients since 30 years. Meta-analysis has shown the benefits on autonomy and mortality. But benefits are related to the organization of geriatric care, especially when integrated care is provided. Literature on geriatric oncology is relatively poor. But it is certain that a geriatric comprehensive assessment provided a lot of important information for the care of cancer patients, leading to a modification of cancer treatment in many cases. Randomized trials will soon begin to evaluate the benefits of geriatric integrated care for elder cancer patients, in terms of mortality and quality of life. Actually, in oncogeriatic coordination units, pilot organizations are developed for the satisfaction of patients and professionals.
Copyright © 2015 Société française de radiothérapie oncologique (SFRO). Published by Elsevier SAS. All rights reserved.

Entities:  

Keywords:  Fragilité; Frailty; Geriatric intervention; Geriatric oncology; Integrated care; Intervention gériatrique; Oncogériatrie; Soins intégrés

Mesh:

Year:  2015        PMID: 26344438     DOI: 10.1016/j.canrad.2015.07.017

Source DB:  PubMed          Journal:  Cancer Radiother        ISSN: 1278-3218            Impact factor:   1.018


  3 in total

1.  Nab-paclitaxel as First Line Treatment for NSCLC in Elderly Patients More Than 75 Years Old.

Authors:  Paul Zarogoulidis; Haidong Huang; Chong Bai; Dimitris Petridis; Susana Papadopoulou; Eleni Faniadou; Ellada Eleftheriadou; Georgia Trakada; Kosmidis Cristoforos; Aggeliki Rapti; Lonny Yarmus; David-Feller Kopman; Yan-Gao Man; Wolfgang Hohenforst-Schmidt
Journal:  J Cancer       Date:  2017-06-04       Impact factor: 4.207

2.  A phase I study of afatinib for patients aged 75 or older with advanced non-small cell lung cancer harboring EGFR mutations.

Authors:  Hisashi Tanaka; Kageaki Taima; Yoshihito Tanaka; Masamichi Itoga; Yoshiko Ishioka; Hideyuki Nakagawa; Keisuke Baba; Yukihiro Hasegawa; Shingo Takanashi; Sadatomo Tasaka
Journal:  Med Oncol       Date:  2018-02-08       Impact factor: 3.064

3.  Regional disease in head and neck cutaneous squamous cell carcinoma: the role of primary tumor characteristics and number of nodal metastases.

Authors:  Alberto Grammatica; Michele Tomasoni; Milena Fior; Emanuela Ulaj; Tommaso Gualtieri; Paolo Bossi; Simonetta Battocchio; Davide Lombardi; Alberto Deganello; Davide Mattavelli; Piero Nicolai; Fabio Girardi; Cesare Piazza
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-06-25       Impact factor: 2.503

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.